April 23, 2026

Regeneron strikes drug pricing deal with Trump administration

Regeneron will lower U.S. drug prices and offer its new hearing-loss gene therapy for free to eligible patients after FDA approval.
This deal is part of President Trump's 'most favored nation' initiative to align U.S. drug prices with those in other developed countries.
The agreement exempts Regeneron from tariffs for three years, as the administration has negotiated similar deals with 17 other drug companies.